The C-terminus of c-Abl is required for proliferation and viability signaling in a c-Abl/erythropoietin receptor fusion protein

Blood

Volumn 92, Issue 10, 1998, Pages 3848-3856

  Okuda, K ^b   D'Andrea, A ^b   Van Etten, R A ^b   Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HYBRID PROTEIN; PROTEIN TYROSINE KINASE;

ADOLESCENT; AMINO ACID SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; DNA FLANKING REGION; DNA REPAIR; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFORMATION; MOUSE; NONHUMAN; NUDE MOUSE; OLIGOMERIZATION; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0032533940     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.10.3848.422k44_3848_3856     Document Type: Article

References (55)

1. Gabert J, Thuret I, Carcassonne Y, Maraninchi D, Mannoni P: Residual bcr/abl transchpts in chronic myeloid leukaemia [letter; comment]. Lancet 335:417, 1990
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765, 1982
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93, 1984
4. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G: Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 315:758, 1985
5. Heisterkamp N, Knoppel E, Groffen J: The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. Nucleic Acids Res 16:10069, 1988
6. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550, 1985
7. Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma RS, Coleman M, Dosik H, Groffen J: Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 313:1429, 1985
8. Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA: The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol 124:325, 1994 (erratum 124:865, 1994)
9. McWhirter JR, Wang JY: Activation of tyrosinase kinase and microfilament-bindmg functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553, 1991
10. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079, 1990
11. Pendergast AM, Muller AJ, Havlik MH, Clark R, McCormick F, Witte ON: Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci USA 88:5927, 1991
12. McWhirter JR, Galasso DL, Wang JY: A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587, 1993
13. Okuda K, D'Andrea A, Etten RA, Griffin JD: A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. J Clin Invest 100:1708, 1997
14. Watowich SS, Hilton DJ, Lodish HF: Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol Cell Biol 14:3535, 1994
15. Andoniou CE, Thien CB, Langdon WY: Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J 13:4515, 1994
16. Matsuguchi I, Salgia R, Hallek M, Eder M, Druker B, Ernst T, Griffin JD: She phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and Steel factor, and is constitutively increased by p210BCR/ABL. J Biol Chem 269:5016, 1994
17. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD: The proto-oncogene product p120(cbl) and the adaptor proteins crkl and c-crk link c-abl, p190(bcr/ abl) and p210(bcr/abl) to the phosphatidylinositol-3′ kinase pathway. Oncogene 12:839, 1996
18. Van Etten RA, Wen S-T, Jackson PK: Multiple nuclear localization signals control the cytostatic effect of c-ABL. Blood 86:324a, 1995 (abstr, suppl 1)
19. Ilaria R Jr, Van Etten RA: The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86:3897, 1995
20. Palacios R, Steinmetz M: IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41:727, 1985
21. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF: The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 11:1980, 1991
22. Okuda K, Golub TR, Gilliland DG, Griffin JD: p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13:1147, 1996
23. Barber DE, DeMartino JC, Showers MO, D'Andrea AD: A dominant negative erythropoietin(EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Mol Cell Biol 14:2257, 1994
24. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD: Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 79:2215, 1992
25. Afar DEA, Goga A, McLaughlin J, Witte ON, Sawyers C: Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424, 1994
26. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N: Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol 11:4710, 1991
27. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]. Blood 88: 2375, 1996
28. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175, 1993
29. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM: The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55:34, 1995
30. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG: Oligomerization of the ABL tyrosine kinase by the Etsprotein TEL in human leukemia. Mol Cell Biol 16:4107, 1996
31. Carlesso N, Griffin JD, Druker BJ: Use of a temperature sensitive mutant to define the biological effects of the p210bcr/abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9:149, 1994
32. Kabarowski JH, Alien PB, Wiedemann LM: A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 13:5887, 1994
33. Jackson P, Baltimore D, Picard D: Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variants. EMBO J 12:2809, 1993
34. Van Etten RA, Smith K: Activation of c-ABL kinase activity and transformation by a chemical inducer of dimerization. Blood 90:247a, 1997 (abstr, suppl 1)
35. Klucher KM, Lopez DV, Daley GQ: Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 90:179a, 1997 (abstr, suppl 1)
36. Wang JY, Baltimore D: Localization of tyrosine kinase-coding region in v-abl oncogene by the expression of v-abl-encoded proteins in bacteria. J Biol Chem 260:64, 1985
37. Salgia R, Li J-L, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Tantravahi R, Chen LB, Griffin JD: Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by p210bcr/abl. J Biol Chem 270:5039, 1995
38. Tauchi T, Feng GS, Shen R, Song HY, Donner D, Pawson T, Broxmeyer HE: SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem 269:15381, 1994
39. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925, 1994
40. Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ: The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia 9:295, 1995
41. Mayer BJ, Jackson PK, Van Etten RA, Baltimore D: Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol 12:609, 1992
42. Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J: Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6:773, 1997
43. Oda T, Kujovich J, Reis M, Newman B, Druker BJ: Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase. Oncogene 15:1255, 1997
44. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B: p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88:197, 1997
45. Van Etten RA, Debnath J, Zhou H, Casasnovas JM: Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene 10:1977, 1995
46. Shi Y, Alin K, Goff SP: Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev 9:2583, 1995
47. Wen ST, Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11:2456, 1997
48. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B: The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: Role in adhesion, invasion, and homing. Blood 91:406, 1998
49. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY: Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmicnuclear transport. Proc Natl Acad Sci USA 93:15174, 1996
50. Van Etten RA, Jackson P, Baltimore D: The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669, 1989
51. Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD: BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100:46, 1997
52. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R: Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92:1925, 1993
53. Verfaillie CM, McCarthy JB, McGlave PB; Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J Clin Invest 90:1232, 1992
54. Bazzoni G, Carlesso N, Griffin JD, Hemler ME: Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 98:521, 1996
55. McWhirter JR, Wang JY: An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533, 1993